CorMedix Inc
NASDAQ:CRMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hangzhou Greatstar Industrial Co Ltd
SZSE:002444
|
CN |
|
N
|
Neuraxis Inc
AMEX:NRXS
|
US |
CorMedix Inc
Total Current Liabilities
CorMedix Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CorMedix Inc
NASDAQ:CRMD
|
Total Current Liabilities
$174.3m
|
CAGR 3-Years
202%
|
CAGR 5-Years
111%
|
CAGR 10-Years
50%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$37B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$35.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
See Also
What is CorMedix Inc's Total Current Liabilities?
Total Current Liabilities
174.3m
USD
Based on the financial report for Dec 31, 2025, CorMedix Inc's Total Current Liabilities amounts to 174.3m USD.
What is CorMedix Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
50%
Over the last year, the Total Current Liabilities growth was 415%. The average annual Total Current Liabilities growth rates for CorMedix Inc have been 202% over the past three years , 111% over the past five years , and 50% over the past ten years .
